Spinal Subpial Gene Delivery for Treatment of Amyotrophic Lateral Sclerosis

脊髓软膜下基因递送治疗肌萎缩侧索硬化症

基本信息

批准号：
10710405
负责人：
MARTIN MARSALA
金额：
$ 63.67万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-28 至 2027-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10710405
关键词：
Adult Aftercare Alleles Amyotrophic Lateral Sclerosis Animal Model Animals Appearance Behavior Biodistribution Clinical Clinical Data Data Development Devices Diagnosis Disease Dose Family suidae Future Gastrocnemius Muscle Gene Delivery Gene Expression Gene Silencing Genes Genome Goals Human Inherited Injections Interneurons Leg Length Life Extension Lumbar spinal cord structure Mediating Methods Modeling Motor Neurons Mus Muscle Mutate Nervous System Physiology Organ Organism Patients Peripheral Proteins Rattus Research Design Rodent Safety Siblings Spinal Spinal Cord Study models Testing Therapeutic Effect Toxic effect Transgenic Organisms Vertebral column Work amyotrophic lateral sclerosis therapy autosome clinically relevant cohort effective therapy end stage disease mouse model novel novel therapeutic intervention pre-clinical preclinical development preservation prototype response small hairpin RNA superoxide dismutase 1 therapy development treatment duration treatment effect vector vector genome white matter

项目摘要

Project Summary Current clinical data show that there is no effective treatment of sporadic or any form of hereditary amyotrophic lateral sclerosis. Our previous work and preliminary data show that two-level spinal subpial delivery of AAV9- shRNA-SOD1 vector is highly effective in blocking the disease development or progression if treatment is initiated in adult pre-symptomatic or early-symptomatic ALS mouse (SOD1G37R) or ALS rat (SOD1G93A). This functionally-defined protection correlated with a high degree of spinal α-motoneuron, interneuron and white matter preservation, and silencing of ALS-causing mutated SOD1 gene expression seen in the entire length of the spinal cord in both mouse and rat ALS models. At present no long post-treatment survival periods have been systemically studied as yet. In our proposed studies, using the SOD1G93A rat model, we will define: i) The maximum duration of clinically defined treatment effect after subpial delivery of AAV9-shRNA-SOD1 in adult pre- symptomatic or early symptomatic SOD1G93A rats. ii) In a separate cohort of wild-type SD rats and pigs, a SOD1 silencing vector will be used to study the toxicity threshold after endogenous SOD1 gene silencing. The aims, research design, and methods have been developed to focus on mutated SOD1 gene-induced ALS, and to generate comprehensive efficacy and initial safety data to support future pre-clinical development of this treatment approach, as a novel therapeutic strategy for augmenting mutated SOD1 gene-caused ALS.

项目摘要当前的临床数据表明，没有有效的零星或任何形式的遗传性肌萎缩治疗侧硬化。我们以前的工作和初步数据表明，AAV9-的两级脊柱亚腹部递送 shRNA-sod1载体在阻止疾病的发展或进展方面非常有效，如果治疗是在成年症状前或早期症状ALS小鼠（SOD1G37R）或ALS大鼠（SOD1G93A）中启动。这功能定义的保护与高度的脊柱α-核神经元，间神经元和白色相关物质保存，以及在整个长度上看到的引起ALS的突变SOD1基因表达的沉默小鼠和大鼠ALS模型中的脊髓。目前尚无长期治疗后的生存期迄今为止进行了系统的研究。在我们提出的研究中，使用SOD1G93A大鼠模型，我们将定义：i）在成年前递送AAV9-shRNA-SOD1后，最大临床定义的治疗效应持续时间有症状或早期的SOD1G93A大鼠。 ii）在单独的野生型SD大鼠和猪中，SOD1 沉默载体将用于研究内源性SOD1基因沉默后的毒性阈值。目的，研究设计和方法已开发出重点是突变的SOD1基因诱导的ALS，以及产生综合效率和初始安全数据，以支持未来的临床前开发治疗方法，是一种增强突变的SOD1基因引起的ALS的新型治疗策略。